These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 32299813)

  • 21. Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer.
    Lazzari L; Corti G; Picco G; Isella C; Montone M; Arcella P; Durinikova E; Zanella ER; Novara L; Barbosa F; Cassingena A; Cancelliere C; Medico E; Sartore-Bianchi A; Siena S; Garnett MJ; Bertotti A; Trusolino L; Di Nicolantonio F; Linnebacher M; Bardelli A; Arena S
    Clin Cancer Res; 2019 Oct; 25(20):6243-6259. PubMed ID: 31375513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
    Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
    J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology.
    Sasaki N; Clevers H
    Curr Opin Genet Dev; 2018 Oct; 52():117-122. PubMed ID: 30261425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
    Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
    Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
    Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
    Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
    Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
    Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Missing metastases as a model to challenge current therapeutic algorithms in colorectal liver metastases.
    Lucidi V; Hendlisz A; Van Laethem JL; Donckier V
    World J Gastroenterol; 2016 Apr; 22(15):3937-44. PubMed ID: 27099436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer.
    Boos SL; Loevenich LP; Vosberg S; Engleitner T; Öllinger R; Kumbrink J; Rokavec M; Michl M; Greif PA; Jung A; Hermeking H; Neumann J; Kirchner T; Rad R; Jung P
    Cell Mol Gastroenterol Hepatol; 2022; 13(2):517-540. PubMed ID: 34700030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
    Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
    Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
    Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
    Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.
    Weeber F; van de Wetering M; Hoogstraat M; Dijkstra KK; Krijgsman O; Kuilman T; Gadellaa-van Hooijdonk CG; van der Velden DL; Peeper DS; Cuppen EP; Vries RG; Clevers H; Voest EE
    Proc Natl Acad Sci U S A; 2015 Oct; 112(43):13308-11. PubMed ID: 26460009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy.
    Mo S; Tang P; Luo W; Zhang L; Li Y; Hu X; Ma X; Chen Y; Bao Y; He X; Fu G; Xu X; Rao X; Li X; Guan R; Chen S; Deng Y; Lv T; Mu P; Zheng Q; Wang S; Liu F; Li Y; Sheng W; Huang D; Hu C; Gao J; Zhang Z; Cai S; Clevers H; Peng J; Hua G
    Adv Sci (Weinh); 2022 Nov; 9(31):e2204097. PubMed ID: 36058001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?
    Lubezky N; Geva R; Shmueli E; Nakache R; Klausner JM; Figer A; Ben-Haim M
    World J Surg; 2009 May; 33(5):1028-34. PubMed ID: 19234865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of liver metastases from colorectal cancer.
    Kemeny N
    Oncology (Williston Park); 2006 Sep; 20(10):1161-76, 1179; discussion 1179-80, 1185-6. PubMed ID: 17024869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro drug testing using patient-derived ovarian cancer organoids.
    Chen LY; Chou YT; Liew PL; Chu LH; Wen KC; Lin SF; Weng YC; Wang HC; Su PH; Lai HC
    J Ovarian Res; 2024 Oct; 17(1):194. PubMed ID: 39358778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management.
    Sutton PA; Jithesh PV; Jones RP; Evans JP; Vimalachandran D; Malik HZ; Park BK; Goldring CE; Palmer DH; Kitteringham NR
    Eur J Surg Oncol; 2018 Jan; 44(1):115-121. PubMed ID: 29174709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study.
    Jensen LH; Rogatto SR; Lindebjerg J; Havelund B; Abildgaard C; do Canto LM; Vagn-Hansen C; Dam C; Rafaelsen S; Hansen TF
    J Exp Clin Cancer Res; 2023 May; 42(1):115. PubMed ID: 37143108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
    Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases.
    Jian M; Ren L; He G; Lin Q; Tang W; Chen Y; Chen J; Liu T; Ji M; Wei Y; Chang W; Xu J
    J Transl Med; 2020 Jun; 18(1):234. PubMed ID: 32532289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges in validation of combination treatment strategies for CRC using patient-derived organoids.
    Benboubker V; Ramzy GM; Jacobs S; Nowak-Sliwinska P
    J Exp Clin Cancer Res; 2024 Sep; 43(1):259. PubMed ID: 39261955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.